#USA #New York #BrainStorm #stem cell #Neurodegenerative

Brainstorm Cell Therapeutics Raises $2 Million

In a significant move for the future of neurodegenerative disorder treatments, Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI) has successfully completed a second strategic placement, raising an additional $1 million, bringing the total funds secured in February 2026 to $2 million. This funding boost marks a positive trajectory for the company, which is actively developing adult stem cell therapies aimed at combatting devastating neurological conditions.

Financial Highlights

The company’s recent financing endeavors were strategically aligned with the fluctuating market, pricing its common stock at $0.60 per share, inline with its recent performance. This placement also comes with high-conviction warrants, allowing investors an exercise price of $1.00 per share. These terms indicate robust interest from institutional partners, highlighting their optimism towards Brainstorm's future developments.

Moreover, this capital influx has been structured through a liquidity ladder, permitting staged investments of up to eight payments. This financial model is designed to provide a steady cash flow, ensuring adequate resources are available to achieve the critical operational goals and preparations for the anticipated Phase 3b trial of NurOwn.

Company Vision and Future Plans

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, articulated the company's vision, emphasizing the importance of this accumulated funding in establishing a firm valuation base while also reflecting the burgeoning market confidence in the company’s potential. The funds will be used to bolster working capital and support ongoing regulatory and clinical programs, which are essential for advancing research on their innovative therapies.

The core product, NurOwn®, employs autologous mesenchymal stem cells (MSCs), designed to deliver neurotrophic factors targeted at modulating neuroinflammation and promoting neuroprotection. This promising technology stands at the crossroads of advanced biomedical therapy and real-world applications aimed at treating disorders such as amyotrophic lateral sclerosis (ALS).

Brainstorm is on the verge of initiating its second Phase 3b trial following a Special Protocol Assessment (SPA) agreement with the FDA, which is a testament to the potential and credibility of its treatment strategies in formal clinical settings.

Diversification and Future Prospects

In addition to its ALS-focused initiatives, the company is making strides in further areas, including ongoing trials in progressive multiple sclerosis, backed by national grant support, reinforcing Brainstorm's commitment to tackling multiple neurodegenerative conditions.

Additionally, Brainstorm has recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent related to its groundbreaking exosome technology, which promises to open new avenues in regenerative medicine. This diversification strategy not only fortifies the company's intellectual property portfolio but also enhances its market relevancy in the fast-evolving biopharmaceutical landscape.

As Brainstorm Cell Therapeutics continues to build upon its successes in securing necessary capital, the scientific and investor communities are watching closely. Their strategic positioning within the complex neural therapy market places them at a unique advantage, potentially leading to future milestones that could dramatically impact patient lives and the broader healthcare landscape. The convergence of clinical findings and strong market support sets a hopeful tone for the ongoing research and implementation of Neurodegenerative disease therapies, and Brainstorm appears well-defined to play a key role in this transformative field.